Estrada M P, Hernández L, Pérez A, Rodríguez P, Serrano R, Rubiera R, Pedraza A, Padrón G, Antuch W, de la Fuente J
Mammalian Cell Genetics Division, Centro de Ingeniería Genética y Biotecnología, Havana, Cuba.
Biotechnology (N Y). 1992 Oct;10(10):1138-42. doi: 10.1038/nbt1092-1138.
Streptokinase (SK), which activates human plasminogen by promoting its conversion to plasmin, is normally obtained from beta-hemolytic streptococci. Treatment with SK is an effective therapy for improving survival and preserving left ventricular function after coronary thrombosis. We report the cloning, expression in E. coli to levels of 25% of the total cell protein, and characterization of a novel SK (SKC-2) gene, the product of which is functionally equivalent to the naturally-derived protein. The availability of a recombinant streptokinase (rSK) in high yield and purity offers a potentially attractive alternative source of this important therapeutic agent.
链激酶（SK）通过促进人纤溶酶原转化为纤溶酶来激活它，通常从β-溶血性链球菌中获得。用SK治疗是改善冠状动脉血栓形成后生存率和保留左心室功能的有效疗法。我们报告了一种新型SK（SKC-2）基因的克隆、在大肠杆菌中表达至总细胞蛋白的25%水平以及特性鉴定，其产物在功能上等同于天然来源的蛋白质。高产量和高纯度的重组链激酶（rSK）的可得性为这种重要治疗剂提供了一个潜在有吸引力的替代来源。
